Advertisement
| breast cancer hormone therapy and osteoporosis: Bone Health and Osteoporosis United States Public Health Service, Surgeon General of the United States, 2004-12 This first-ever Surgeon General's Report on bone health and osteoporosis illustrates the large burden that bone disease places on our Nation and its citizens. Like other chronic diseases that disproportionately affect the elderly, the prevalence of bone disease and fractures is projected to increase markedly as the population ages. If these predictions come true, bone disease and fractures will have a tremendous negative impact on the future well-being of Americans. But as this report makes clear, they need not come true: by working together we can change the picture of aging in America. Osteoporosis, fractures, and other chronic diseases no longer should be thought of as an inevitable part of growing old. By focusing on prevention and lifestyle changes, including physical activity and nutrition, as well as early diagnosis and appropriate treatment, Americans can avoid much of the damaging impact of bone disease and other chronic diseases. This Surgeon General's Report brings together for the first time the scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. More importantly, it provides a framework for moving forward. The report will be another effective tool in educating Americans about how they can promote bone health throughout their lives. This first-ever Surgeon General's Report on bone health and osteoporosis provides much needed information on bone health, an often overlooked aspect of physical health. This report follows in the tradition of previous Surgeon Generals' reports by identifying the relevant scientific data, rigorously evaluating and summarizing the evidence, and determining conclusions. |
| breast cancer hormone therapy and osteoporosis: Prevention of Bone Metastases Markus Joerger, Michael Gnant, 2012-01-05 Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab. |
| breast cancer hormone therapy and osteoporosis: Treatment of the Postmenopausal Woman Rogerio A. Lobo, 2007-06-05 For anyone who treats postmenopausal women, this latest edition of Rogerio Lobo's classic work combines the best from two well-known references: Menopause, and the second edition of Treatment of the Postmenopausal Woman. By adding significant discussions of the basic science behind menopause, it is possible to objectively assess the clinical value and limitations of current approaches to treatment and provide a basis and rationale for strategies that will result in better individualized and specialized care. Not only does the third edition discuss diagnosis and treatment of menopause but it covers biological, anatomical, physiological, pathobiological, and pharmacological aspects as well bringing together, in one source, all of the information needed to understand and treat postmenopausal conditions. Over 50% new material representing the vast amount of information available since the Women's Health Initiative (WHI) clinical trials were completed making this the most up-to-date reference on postmenopausal women Includes several new sections on comparisons between clinical trials and observational data, urology, and pelvic support Each section is preceded by a preface to put the area into context with many chapters having suggested treatment regimens |
| breast cancer hormone therapy and osteoporosis: Estrogen Matters Carol Tavris, Avrum Bluming, 2018-09-04 A compelling, “fascinating” (Robert Cialdini) defense of hormone replacement therapy, exposing the faulty science behind its fall from prominence and giving women the evidence they need to make informed decisions about their health. Now fully revised and updated. Estrogen Matters was my antidote to the misinformation surrounding menopause. This book should be the bible for every single person going through menopause.”―Naomi Watts For years, hormone replacement therapy (HRT) was the medically approved way to alleviate menopausal symptoms (ranging from hot flushes to brain fog) and reduce the risk of heart disease, Alzheimer's, and osteoporosis. But when a large study by the Women's Health Initiative (WHI) announced, with national fanfare, that women taking HRT had an increased risk of breast cancer, women were scared off, and the treatment was abandoned. Now, Dr. Bluming, a medical oncologist, and Dr. Tavris, a social psychologist, reveal the true story of the WHI’s efforts to distort their data to exaggerate unsupported claims of estrogen’s harms. Important updates in this edition include: Evidence that demolishes the WHI’s claim that HRT causes breast cancer. A list of the WHI’s retractions of their original scare stories. Updated findings on estrogen’s benefits on heart, brain, bones, and longevity. A critical review of the alternative products and medications being marketed to treat symptoms of menopause. A sobering and revelatory read, Estrogen Matters sets the record straight on estrogen’s benefits, providing a light to guide women through this inevitable phase of life. |
| breast cancer hormone therapy and osteoporosis: Osteoporosis Steven R. Cummings, Felicia Cosman, Sophie A. Jamal, 2002 Until recently considered an inevitable part of aging, osteoporosis is typically diagnosed only after a serious complication such as a fracture. It is now possible, however, to diagnose high-risk patients beforehand. Easily performed noninvasive tests estimate bone mass, and patients at risk can be treated with new drugs whose efficacy for fracture reduction has been proven in clinical trials. Osteoporosis: An Evidence-Based Guide to Prevention and Management, the newest volume in the acclaimed ACP Women's Health series, addresses every important facet of this common disease. The latest scientific evidence and the extensive clinical experience of the authors provide essential information on the origins and progress of osteoporosis. Treatment options are thoroughly reviewed. |
| breast cancer hormone therapy and osteoporosis: Clinical Gynecology Eric J. Bieber, Joseph S. Sanfilippo, Ira R. Horowitz, Mahmood I. Shafi, 2015-04-23 Written with the busy practice in mind, this book delivers clinically focused, evidence-based gynecology guidance in a quick-reference format. It explores etiology, screening, tests, diagnosis, and treatment for a full range of gynecologic health issues. The coverage includes the full range of gynecologic malignancies, reproductive endocrinology and infertility, infectious diseases, urogynecologic problems, gynecologic concerns in children and adolescents, and surgical interventions including minimally invasive surgical procedures. Information is easy to find and absorb owing to the extensive use of full-color diagrams, algorithms, and illustrations. The new edition has been expanded to include aspects of gynecology important in international and resource-poor settings. |
| breast cancer hormone therapy and osteoporosis: Osteoporosis in Men Eric S. Orwoll, John P. Bilezikian, Dirk Vanderschueren, 2009-11-30 Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger – 8.5 x 11. This edition of Osteoporosis in Men brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy. - Brings together more eminent investigators and clinicians to interpret developments in this growing field - Describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy - There is no book on the market that covers osteoporosis in men as comprehensively as this book |
| breast cancer hormone therapy and osteoporosis: Marcus and Feldman's Osteoporosis David W. Dempster, Jane A. Cauley, Mary L. Bouxsein, Felicia Cosman, 2020-10-08 Marcus and Feldman's Osteoporosis, Fifth Edition, is the most comprehensive, authoritative reference on this disease. Led by a new editorial team, this fifth edition offers critical information on reproductive and hormonal risk factors, new therapeutics, ethnicity, nutrition, therapeutics, management and economics, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume reference is a must-have for biomedical researchers, research clinicians, fellows, academic and medical libraries, and any company involved in osteoporosis drug research and development. - Summarizes the latest research in bone biology and translational applications in a range of new therapeutic agents, including essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, parathyroid hormone, and new therapeutic agents - Recognizes the critical importance of new signaling pathways for bone health, including Wnt, OPG and RANK, of interest to both researchers who study bone biology and clinicians who treat osteoporosis - Offers new insights into osteoporosis associated with menopause, pre-menopause, chronic kidney disease, diabetes, HIV and other immune disorders |
| breast cancer hormone therapy and osteoporosis: Pocket Reference to Osteoporosis Serge Livio Ferrari, Christian Roux, 2018-12-28 This book responds to the daily needs of all clinicians treating patients with osteoporosis and provides a key reference guide for any challenges that arise in clinical practice. This book also covers the genetics of the disease, clinical presentation, diagnosis, and current and upcoming treatment recommendations in accordance with the latest international guidelines. Osteoporosis is a disease in which the density and quality of bone are greatly reduced, and as bones become more porous and fragile the risk of fracture increases greatly. It is one of the most common metabolic bone diseases globally with one in three women and one in five men at risk of an osteoporotic fracture, and can result in devastating physical, psychosocial, and economic consequences. However, in spite of this osteoporosis can often be overlooked and undertreated, thus there is a real need to raise awareness of this disease. |
| breast cancer hormone therapy and osteoporosis: Endocrine and Metabolic Late Effects in Cancer Survivors Francesco Felicetti (Oncologist), Enrico Brignardello, Hanneke M. van Santen, 2021-11 This book analyzes in detail all aspects related to endocrine and metabolic late effects observed in patients treated for cancer, both in childhood and adulthood. The chapters focusing on the possible pathogenic mechanisms of late effects (i.e., premature aging and chronic inflammation) and on bone health in cancer survivors are particularly interesting and innovative. The volume also deals with hypothalamic-pituitary, thyroid and gonadal disorders, including infertility and how to prevent it. Finally, the relationship between metabolic alterations and cardiovascular diseases in cancer survivors is addressed. Thanks to advances in cancer treatment and supportive care, the five-year survival rate of cancer patients is constantly increasing. However, this undisputable success of medicine has a flip side: the late adverse effects of anticancer therapies. Pediatric oncologists were the first to cope with late complications of treatments, but today also adult oncologists and onco-hematologists recognize the relevance of this issue. Even though late effects observed in cancer survivors can affect any organ or system, endocrine and metabolic dysfunctions are the most frequently reported. Endocrine complications rarely influence life expectancy of cancer survivors, but they can significantly impact morbidity and quality of life. Among endocrine adverse effects, severe hypothalamic damage may be considered the most harmful in survivors, leading to morbid obesity, propensity to metabolic syndrome and cardiovascular disease. This book aims to disseminate the knowledge about endocrine and metabolic adverse effects of cancer therapies and about survivorship care. Since the number of cancer survivors is steadily growing in the general population, this publication is intended not only for endocrinologists but also for oncologists, onco-hematologists, internists, pediatric specialists in those areas and general practitioners, with the aim to better counsel and monitor cancer survivors. |
| breast cancer hormone therapy and osteoporosis: The Osteoporosis Manual Reiner Bartl, Christoph Bartl, 2019-02-06 This comprehensive manual covers all aspects of the prevention, diagnosis and management of osteoporosis, offering an upbeat and optimistic assessment of what can be achieved. While scientifically based, the book provides easy-to-follow guidelines for lifelong maintenance of skeletal structure and function. It deals with everything from the basic physiology of bone and mineral metabolism to the diagnostic utility of radiologic imaging and specialized tests and current treatment recommendations, including for fracture management. The relationship of osteoporosis to a variety of other disorders is also thoroughly explored and elucidated. Osteoporosis represents a global threat because every human being is vulnerable to it as time passes. The authors point out the enormous scale of the problem in terms of the human suffering, morbidity, and mortality on the one hand and the associated astronomical national and global costs on the other. Osteoporosis is preventable, and every doctor in every medical discipline can contribute to this goal. And though prevention is better than cure, it is never too late for effective therapy, as outlined in this book. Bone is every doctorʼs and every bodyʼs business! |
| breast cancer hormone therapy and osteoporosis: Practical Guide to Oral Exams in Obstetrics and Gynecology Görker Sel, 2019-11-13 This book, based on non-interactive question-and-answer format, offers an essential guide for medical students who need to prepare for oral exams or clinical visits. Starting from specific clinical situations the volume provides clear questions on the theory related to the cases. Each question is followed by correct answers that summarize the main information. Suggested reading are included to deepen the topics and enhance the readers knowledge. Accordingly, this practical guide will help students get ready for their oral exams, and help prepare young residents for their first clinical cases. |
| breast cancer hormone therapy and osteoporosis: Adjuvant Therapy of Breast Cancer I. Craig Henderson, 2012-11-05 The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy. |
| breast cancer hormone therapy and osteoporosis: Endocrine Secrets Michael T. McDermott, MD, 2013-04-18 The thoroughly updated Endocrine Secrets, 6th Edition continues the tradition of the highly popular Secrets Series®, offering fast answers to the most essential clinical endocrinology questions. A user-friendly Q&A format, replete with valuable pearls, tips, and memory aids, helps you to learn and study efficiently. It all adds up to a perfect concise board review or handy clinical endocrinology resource. Expedite your reference and review with a question-and-answer format that's conversational and easy to read. Zero in on key information with bulleted lists, mnemonics, practical tips from prominent endocrinologists, and Key Points boxes that provide a concise overview of important board-relevant content. Quickly review essential material with a chapter containing the Top 100 Secrets in endocrinology. Take your Secrets anywhere thanks to a convenient, pocket-sized design! Remain at the forefront of medical endocrinology with updates on new techniques and technologies, as well as changing treatment options and drug information. Equip yourself for effective practice with coverage of the most current developments in obesity management, weight loss drugs, and bariatric surgery; the newest guidelines for the pharmacological treatment of type 2 diabetes mellitus; and much more. Make use of practical tips on intensive insulin therapy, and apply evidence-based techniques to achieve appropriate glucose control in hospitalized patients and effectively manage thyroid cancer. Access the latest research concerning the benefits and risks of the wide range of osteoporosis therapies. |
| breast cancer hormone therapy and osteoporosis: Glucocorticoid-induced Osteoporosis Andrea Giustina, Alberto Angeli, Ernesto Canalis, 2002 Osteoporosis is one of the most clinically relevant disabling chronic disease encountered in clinical practice. A common cause of osteoporosis is glucocorticoid excess, as glucocorticoids may increase bone resorption, inhibit bone formation, have indirect actions on bone by decreasing intestinal calcium absorption and induce hypercalciuria. This book presents a comprehensive overview of the effects of glucocorticoids on bone metabolism and structure and on the diagnosis and treatment of glucocorticoid-induced osteoporosis. It aims at providing updated information on the pathogenesis, diagnosis and treatment of this often dramatic complication of glucocorticoid excess. Being one of the few publications completely devoted to glucocorticoid-induced osteoporosis it will heighten the awareness of specialists who prescribe glucocorticoids of the clinical relevance of this treatment complication. 'Glucocorticoid-Induced Osteoporosis' is addressed to clinical experts as well as to general practitioners who will both benefit from the comprehensive and integrative view of the management of patients exposed to glucocorticoids. |
| breast cancer hormone therapy and osteoporosis: Endocrinology S.S. Nussey, S.A. Whitehead, 2001-06-15 Traditionally, endocrinology textbooks have been either short notes or multi-author, multi-volume monster, all of which present clinical material last and often only briefly. Endocrinology is different and used real cases to lead readers into the text and then describes the biochemistry, physiology, and anatomy they need to understand the case. The |
| breast cancer hormone therapy and osteoporosis: Bisphosphonates in Bone Disease Herbert Fleisch, 2000-04-18 This book is an essential handbook on bisphosphonates, the most widely used new class of drugs for osteoporosis therapy. It reviews basic physiology in addition to the indications and adverse reactions of these drugs. Bisphosphonates in Bone Disease, 4E, discusses the compounds' chemistry, mechanisms of action, and animal toxicology before presenting a clinical picture of the diseases treated by bisphosphonates. The book provides a table listing the trade names of the commercially available bisphosphonates, registered indications, and the available forms for various countries. The revised Fourth Edition contains approximately 50% new material, including information on all of the latest drugs. * The revised fourth edition contains approximately 50% new material * Includes information on all the latest drugs |
| breast cancer hormone therapy and osteoporosis: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| breast cancer hormone therapy and osteoporosis: Geriatric Rehabilitation Manual Timothy L. Kauffman, John O. Barr, Michael L. Moran, 2007-01-01 This manual gives step-by-step guidance on the evaluation and treatment of geriatric diseases and disorders. It covers incidence of disorders, diagnostic tests, associated diagnoses, clinical implications for mobility, and rehabilitation techniques. It offers a broad overview of the effects of aging on all body systems. Special geriatric considerations for laboratory assessment, thermoregulations, and pharmacology are also discussed. This manual is a resource for all training clinicians in geriatric care and is a quick-reference guide for students and practitioners in this field. |
| breast cancer hormone therapy and osteoporosis: New Horizons in Osteoporosis Management Yasser El Miedany, 2022-01-03 This book provides a review of the most recent data on osteoporosis and bone health, presenting a vision of diagnosis and management for the year 2021 and beyond. It covers all pertinent aspects of bone health including diagnosis, fracture prevention, optimized practice, impaired orthostasis, and falls. The book examines recent developments in therapeutics, including goal-directed therapy, individualizing therapy, sequential and combined therapies, pharmaceuticals, and anabolic vs. antiresorptive therapy. In addition, it provides an in-depth overview of osteoporosis and bone health in complex patients, covering Duchene dystrophy, renal failure, periodontal diseases, and steroid-induced osteoporosis as well as considerations for pediatric populations and men. New Horizons in Osteoporosis Management is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses in rheumatology, endocrinology, radiology, pediatrics, primary care, and internal medicine. |
| breast cancer hormone therapy and osteoporosis: Contemporary Internal Medicine Juan M. Bowen, Ernest L. Mazzaferri, 2013-06-29 In the previous two volumes of this series, we presented classic problems in internal medicine as illustrated by actual cases cared for in our institution. It has been gratifying for us to see the interest that these volumes have generated with students and trainees. We remain committed to the case method of instruction, and believe that there is no better method to learn medicine than to have an individual patient problem as the basis for study of pathophysiology, natural history, diagnosis and management. We hope that our readers find this third volume as enjoyable and instructive as the editors found it. Juan M. Bowen, MD Ernest L. Mazzaferri, MD, FACP xiii Acknowledgement The editors are grateful to Jeff Smith and Jenny Riegler for their unflagging professionalism and patience. xiv Contents Case 1 Mitral Regurgitation - Chronic Versus Acute: Implications for Timing of Surgery • . • • • . . • . . . . . • . . . . . . . . . . . 1 Harisios Boudoulas, MD Charles F. Wooley, MD Advances and diagnostic imaging in a surgical technique have changed the approach to mitral valve regurgitation. This chapter provides an expert's perspective. Case 2 Cystic Fibrosis in Adults .. • •••••••••••• 36 Andrew Libertin, MD John S. Heintz, MD As children with cystic fibrosis grow into adulthood, the internist assumes a greater role in their care. Case 3 Thrombotic Thrombocytopenic Purpura . . . . . . . . . . 51 . . . Donald E. Thornton, MD Earl N. Metz, MD, FACP Patients with ITP continue to present difficulties in diagnosis and management. Two experts discuss the current approach to ITP. |
| breast cancer hormone therapy and osteoporosis: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| breast cancer hormone therapy and osteoporosis: The Hormone Cure Sara Gottfried, 2014-03-11 A Harvard physician's method to improve physical and mental health by optimizing the hormones in the 30s, 40s, and beyond. |
| breast cancer hormone therapy and osteoporosis: Medical Pharmacology and Therapeutics E-Book Derek G. Waller, Tony Sampson, 2013-08-07 This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice |
| breast cancer hormone therapy and osteoporosis: Diet and Health National Research Council, Division on Earth and Life Studies, Commission on Life Sciences, Committee on Diet and Health, 1989-01-01 Diet and Health examines the many complex issues concerning diet and its role in increasing or decreasing the risk of chronic disease. It proposes dietary recommendations for reducing the risk of the major diseases and causes of death today: atherosclerotic cardiovascular diseases (including heart attack and stroke), cancer, high blood pressure, obesity, osteoporosis, diabetes mellitus, liver disease, and dental caries. |
| breast cancer hormone therapy and osteoporosis: Hormone Replacement: Therapy and Breast Cancer Risk R.D. Mann, 1992-07-15 This book covers a topic of considerable current interest and presents many of the most significant research findings available to date. Workers at the forefront of research on hormone replacement therapy and the implications for the risk of breast cancer were invited to attend a special Conference at the Royal Society of Medicine in London in September, 1991, where the latest data were presented to a distinguished audience and the implications of this research were discussed. The volume reviews various aspects of HRT and breast cancer, the physiology of the menopause, the current use of HRT in practice, osteoporosis and epidemiology and presents results from a range of European, American and Australian studies on the role of breast cancer and HRT, finishing with an overview of benefits, use and cost-effectiveness and a general summary. The book represents a definitive statement of current knowledge in this field and an informative update on the implications of recent research. It will be a valuable addition of special significance to the libraries of all those concerned with hormone replacement therapy and the study of breast cancer. |
| breast cancer hormone therapy and osteoporosis: Hormone Replacement Therapy and Osteoporosis J. Kato, H. Minaguchi, Y. Nishino, 2013-06-29 Many women have to spend one third of their lives in a postmenopausal state and they should have a good quality of life during this period. Althoug HRT is well accepted as the logical treatment of climacteric problems, the prevalence rate is very low in some countries. The reasons for not accepting HRT are manifold and complex. The objective of this book is to describe the essential advances in basic and clinical research that forms the basis of current HRT and to give an overview of the efficacy and safety of HRT. |
| breast cancer hormone therapy and osteoporosis: The Breast K. I. Bland, Edward M. Copeland, 2009 Offering the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast, this surgical reference is now in a new edition available in both print and online for easy, convenient access to the absolute latest advances. |
| breast cancer hormone therapy and osteoporosis: Your Bones Lara Pizzorno, Jonathan V. Wright, 2013 You are at risk for osteoporosis. If you are a woman, you're at high risk for osteoporosis -- Why conventional medicine is not the answer for strong bones. The patent medicines prescribed to prevent osteoporosis should be your last choice for healthy bones -- What increases your risk for osteoporosis? What you don't know can give you osteoporosis ; What else increases my risk for osteoporosis ; What men don't know can increase their risk for osteoporosis ; Chances are, you are already losing bone -- How to have strong bones for life. Strong bones for life, naturally -- If I follow these recommendations, what can I expect? How soon will I see results? |
| breast cancer hormone therapy and osteoporosis: Advances in the Treatment of Hormonal Receptor positive (HR+) Breast Cancer Deniz Can Guven , Arunasalam Dharmarajan, Wala Ben Kridis, 2024-10-09 Breast cancer is the most common cancer in women. Breast cancer subtypes are classified according to histologic features, including morphology and receptor status. Information on the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), as well as the proliferation index Ki67 (in early-stage disease), are relevant for clinical decisions. Molecular tests are now available to further classify the disease into subgroups, stratify risk or estimate the benefit of interventions. Some examples of such tests include the Recurrence Score (OncotypeDX), PAM50 (Prosigna), Mammaprint, Blueprint, and Breast Cancer Index (BCI), among others. |
| breast cancer hormone therapy and osteoporosis: The Osteoporosis Primer Janet E. Henderson, David Goltzman, 2000-08-24 The Osteoporosis Primer provides an excellent introduction that relates the clinical presentation of osteoporosis to its molecular biochemical basis, and reviews therapeutic options. |
| breast cancer hormone therapy and osteoporosis: HRT and Osteoporosis James O. Drife, John W.W. Studd, 2012-12-06 HRT and Osteoporosis is a response to the increasing awareness among both the medical profession and the general public that ovarian failure is an important cause of osteoporosis and that much of the bone loss after the menopause can be prevented by oestrogen treatment. There is now an urgent need on the part of women, their doctors and those responsible for public health policy for practical guidance on such questions as the safety and acceptability of long-term treatment with sex hormones, the economic costs and benefits of such treatment, and the role of specialists and GPs in promoting and monitoring hormone replacement therapy. All these issues and more are considered here. The book comprehensively reviews current knowledge of the subject and gives recommendations for clinical practice and future research. |
| breast cancer hormone therapy and osteoporosis: Effectiveness and costs of osteoporosis screening and hormone replacement therapy , |
| breast cancer hormone therapy and osteoporosis: Drug Therapy for Osteoporosis Michael Kleerekoper, 2004-12-02 Hormone replacement is clearly indicated for the prevention and treatment of osteoporosis. Although its importance in treating this disease is no longer questioned, much remains to be fully understood about its effective application in practice. Drug Therapy for Osteoporosis examines what is known about the progress of osteoporosis and describes the impact of hormone replacement therapy. The author reviews the option for using SERMs as opposed to conventional HRT regimens, discusses not only the effectiveness of treatment but also the recommended duration, and provides clear guidelines on the laboratory evaluation of osteoporosis. |
| breast cancer hormone therapy and osteoporosis: Clinical Trials in Osteoporosis Derek Pearson, Colin G. Miller, 2013-03-14 Clinical Trials in Osteoporosis is a practical handbook on clinical trials in the growing field of osteoporosis. Topics covered include study design, technical issues, data collection, quality assurance, data analysis and presentation. It aims to take the user through the process step-by-step from start to finish, also providing a background on regulatory guidelines, ethical implications, endpoints, current therapies and the ideal drug to use. There are no other books at present that specifically address the issue of clinical trials in osteoporosis. A number of issues dealt with in this book have been brought together in one publication for the first time. Clinical Trials in Osteoporosis is intended to serve as a practical manual for clinicians and scientists coming to the subject new and to provide a standard for existing centers to measure themselves against. |
| breast cancer hormone therapy and osteoporosis: Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy: Evidence on benefits, risks, and costs , 1995 |
| breast cancer hormone therapy and osteoporosis: Hormone Replacement Therapy and Cancer Andrea R. Genazzani, 2020-07-26 The clinical benefits of hormone replacement therapy in women have to be carefully balanced against the possible risks, and a particular theoretical concern relates to risks associated with various forms of female oncology. Because of conflicting reports, gynecologists and oncologists especially need a single, authoritative resource of up-to-date information. Hormone Replacement Therapy and Cancer, published in association with the International Menopause Society, provides the very consensus statement that clinicians need in this difficult and complex area. Many of the world's leading specialists have contributed important chapters that provide state-of-the-art knowledge about the effects of hormones on women and possible cancer risks. The introductory section deals with carcinogenesis, and the other main sections cover HRT and breast cancer, endometrial cancer, colon cancer, melanoma and epithelial ovarian cancer. The concluding chapters discuss the benefits and risks of sp ecific therapies. An authoritative clinical reference with extensive bibliographic references and index, Hormone Replacement Therapy and Cancer covers all aspects of HRT and cancer based on the research available up to June 2001. |
| breast cancer hormone therapy and osteoporosis: The Prescriber's Guide to Hormone Replacement Therapy M.I. Whitehead, 1998-08-15 Drawing together many of the world's foremost experts, this book provides clear and specific guidance about the prescription of hormone replacement therapy. It covers prescribing for patients with a wide range of pre-existing diseases. In each instance, expert advice is given with reference to the latest published research. There is also an overview of other key issues affecting the choice of therapy. |
| breast cancer hormone therapy and osteoporosis: Osteoporosis Robert Marcus, David W. Dempster, Jane A. Cauley, David Feldman, 2013-06-13 Now in its fourth edition, Osteoporosis is a classic reference on this disease, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume work is a must-have for academic and medical libraries, physicians, researchers, and any company involved in osteoporosis research and development. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in which direct care costs for osteoporotic fractures in the United States reach up to $18 billion each year. Worldwide, 200 million women ages 60 to 80 suffer from osteoporosis and have a lifetime risk of fracture between 30% and 40%, continuing to make osteoporosis a critical challenge in medicine. - Recognizes the critical importance of the Wnt signaling pathway for bone health - Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone - Examines essential updates on estrogen prevention and treatment and the recent results from the WHO - Discusses the controversial topics of screening and clinical trial design for drug registration - Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone - Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics |
| breast cancer hormone therapy and osteoporosis: Osteoporosis: A Guide to Prevention & Treatment Robert H. Lindsay, 1992 |
Postmenopausal Osteoporosis in Women with Breast Cancer
postmenopausal women with breast cancer. •Recognize drug-related bone loss in postmenopausal women treated for breast cancer. •Use pharmacologic interventions to …
Guidance for the Management of Breast Cancer Treatment …
Breast cancer treatments associated with ovarian suppression sA number of breast cancer treatments are associated with premature ovarian suppression, including treatment with …
Managing Bone Health in Breast Cancer - Endocrine
Dec 10, 2022 · endocrine treatments for hormone receptorepositive breast cancer and the current use of anti-resorptive agents as adjuvant therapy and as bone modifying agents. Results: …
Breast cancer treatments and osteoporosis - Royal …
Breast cancer may also be treated with drug treatments (‘chemotherapy’) that directly target breast cancer cells. Do these treatments cause osteoporosis and fractures? It is now well …
Bone health during endocrine therapy for cancer - The Lancet
Endocrine therapy, a mainstay treatment in the management of patients with hormone-sensitive breast and prostate cancer in the adjuvant setting, commonly exerts adverse efects on the …
Management of bone loss due to endocrine therapy during …
HR+ breast cancer and NMPC are at the risk of bone loss due to bone metastasis and standard adjuvant endocrine, cytotoxic, and targeted treatments, thus increasing the popu-lation of …
782FM.3 GUIDANCE FOR THE MANAGEMENT OF BREAST …
Aromatase inhibitors (AIs) including anastrozole, letrozole and exemestane, are treatment of choice in postmenopausal women with hormone responsive breast cancer. They supress …
Osteoporosis therapy and outcomes for postmenopausal …
BACKGROUND: Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of …
New-onset osteopenia/osteoporosis among long-term …
New-onset osteopenia/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors. Background: Anti-cancer therapies (including aromatase …
Osteoporosis and breast cancer treatment
Some treatments for breast cancer can affect your bones which can then increase your risk of developing osteoporosis in the future. This booklet explains what osteoporosis is, why the …
Osteoporosis management in patients with breast cancer: …
clinical trials of antifracture therapy in women with early-stage breast cancer and discusses current guidelines for the management of osteoporosis in women with breast cancer. It also …
Women’s health 2019: Osteoporosis, breast cancer, …
Osteoporosis, breast cancer, contraception, and hormone therapy Keeping up with current evidence-based healthcare practices is key to providing good clinical care to patients. This …
Hormone therapy and osteoporosis in breast cancer survivors …
Introduction A case-cohort study was undertaken to better understand the impact of hormone therapy on breast cancer patients’ risk of osteoporosis, and to estimate the extent to which …
Management of cancer treatment-induced bone loss in early …
Chemo-therapy, GnRH analogs and tamoxifen can induce marked bone loss in premenopausal women with early breast cancer. Aromatase inhibitors (AIs) are replacing tamoxifen as the …
Menopausal hormone therapy and breast cancer risk
We will discuss how to assess breast cancer risk using internet-based tools, when MHT is considered safe, when one should be cautious when prescribing MHT in a balanced decision …
Clinical Pharmacology Of Selective Oestrogen Receptor …
used to treat a variety of conditions, including ER-positive breast cancer, osteoporosis, coronary heart disease, Alzheimer’s disease, and cholesterol metabolism disorders in postmenopausal …
Osteoporosis and breast cancer treatment
Some treatments for breast cancer can affect your bones, which can increase your risk of developing osteoporosis. This booklet explains what osteoporosis is, why the treatment you’ve …
Hormone Replacement Therapy and the Risk of Breast Cancer
HRT can reduce the risk of osteoporosis (weak bones) in the short term and improve muscle strength. Remaining physically active, maintaining a healthy diet and weight (particularly after …
Prevention and Treatment of Osteoporosis in Women With …
We have reviewed therapeutic alter natives for the prevention and treatment of osteoporosis, focusing on patients with a history of breast cancer. Alendronate and raloxifene are currently …
Postmenopausal Osteoporosis in Women with Breast Cancer
postmenopausal women with breast cancer. •Recognize drug-related bone loss in postmenopausal women treated for breast cancer. •Use pharmacologic interventions to …
Guidance for the Management of Breast Cancer Treatment …
Breast cancer treatments associated with ovarian suppression sA number of breast cancer treatments are associated with premature ovarian suppression, including treatment with …
Breast Cancer - Bone Health & Osteoporosis Foundation
Aromatase inhibitors are hormone therapies used to treat estrogen receptor-positive breast cancer in postmenopausal women. These evidence-based treatments keep cancer cells from …
Managing Bone Health in Breast Cancer - Endocrine
Dec 10, 2022 · endocrine treatments for hormone receptorepositive breast cancer and the current use of anti-resorptive agents as adjuvant therapy and as bone modifying agents. Results: …
Breast cancer treatments and osteoporosis - Royal …
Breast cancer may also be treated with drug treatments (‘chemotherapy’) that directly target breast cancer cells. Do these treatments cause osteoporosis and fractures? It is now well …
Bone health during endocrine therapy for cancer - The Lancet
Endocrine therapy, a mainstay treatment in the management of patients with hormone-sensitive breast and prostate cancer in the adjuvant setting, commonly exerts adverse efects on the …
Management of bone loss due to endocrine therapy during …
HR+ breast cancer and NMPC are at the risk of bone loss due to bone metastasis and standard adjuvant endocrine, cytotoxic, and targeted treatments, thus increasing the popu-lation of …
782FM.3 GUIDANCE FOR THE MANAGEMENT OF BREAST …
Aromatase inhibitors (AIs) including anastrozole, letrozole and exemestane, are treatment of choice in postmenopausal women with hormone responsive breast cancer. They supress …
Osteoporosis therapy and outcomes for postmenopausal …
BACKGROUND: Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of …
New-onset osteopenia/osteoporosis among long-term …
New-onset osteopenia/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors. Background: Anti-cancer therapies (including aromatase …
Osteoporosis and breast cancer treatment
Some treatments for breast cancer can affect your bones which can then increase your risk of developing osteoporosis in the future. This booklet explains what osteoporosis is, why the …
Osteoporosis management in patients with breast cancer: …
clinical trials of antifracture therapy in women with early-stage breast cancer and discusses current guidelines for the management of osteoporosis in women with breast cancer. It also …
Women’s health 2019: Osteoporosis, breast cancer, …
Osteoporosis, breast cancer, contraception, and hormone therapy Keeping up with current evidence-based healthcare practices is key to providing good clinical care to patients. This …
Hormone therapy and osteoporosis in breast cancer …
Introduction A case-cohort study was undertaken to better understand the impact of hormone therapy on breast cancer patients’ risk of osteoporosis, and to estimate the extent to which …
Management of cancer treatment-induced bone loss in early …
Chemo-therapy, GnRH analogs and tamoxifen can induce marked bone loss in premenopausal women with early breast cancer. Aromatase inhibitors (AIs) are replacing tamoxifen as the …
Menopausal hormone therapy and breast cancer risk
We will discuss how to assess breast cancer risk using internet-based tools, when MHT is considered safe, when one should be cautious when prescribing MHT in a balanced decision …
Clinical Pharmacology Of Selective Oestrogen Receptor …
used to treat a variety of conditions, including ER-positive breast cancer, osteoporosis, coronary heart disease, Alzheimer’s disease, and cholesterol metabolism disorders in postmenopausal …
Osteoporosis and breast cancer treatment
Some treatments for breast cancer can affect your bones, which can increase your risk of developing osteoporosis. This booklet explains what osteoporosis is, why the treatment you’ve …
Hormone Replacement Therapy and the Risk of Breast Cancer
HRT can reduce the risk of osteoporosis (weak bones) in the short term and improve muscle strength. Remaining physically active, maintaining a healthy diet and weight (particularly after …
Prevention and Treatment of Osteoporosis in Women With …
We have reviewed therapeutic alter natives for the prevention and treatment of osteoporosis, focusing on patients with a history of breast cancer. Alendronate and raloxifene are currently …
